0YX Stock Chart & Stats
€8.47
€0.21(2.52%)
At close: 4:00 PM EDT
€8.47
€0.21(2.52%)
Day’s Range― - ―
52-Week Range€6.51 - €14.90
Previous CloseN/A
Volume0.00
Average Volume (3M)44.00
Market Cap
€5.53B
Enterprise Value€836.79K
Total Cash (Recent Filing)€84.12B
Total Debt (Recent Filing)€70.48B
Price to Earnings (P/E)28.1
Beta0.49
Next Earnings
Aug 07, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)56.89
Shares Outstanding629,480,100
10 Day Avg. Volume113
30 Day Avg. Volume44
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)1.69
Price to Sales (P/S)1.71
P/FCF Ratio20.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.37Price Target Upside10.59% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.37
Revenue Forecast (FY)€2.95B
Bulls Say, Bears Say
Bulls Say
Recurring Revenue Model (consumables & Services)Sysmex's business is anchored by capital instrument placements plus high-frequency consumable and service sales tied to installed systems. That installed-base pull-through creates predictable, recurring revenue and long-term customer stickiness that supports steady cash flows and margin stability.
Historically Healthy MarginsSustained gross and net margins reflect product differentiation and high-margin consumables, shielding profitability from cyclical volume swings. Durable margin structure supports reinvestment in R&D, capacity and service capability, preserving competitive advantage over multi-quarter horizons.
Conservative Balance Sheet And Large Equity BaseA growing equity base and historically low leverage give Sysmex financial flexibility to fund R&D, capital placements and acquisitions, and to sustain dividends or weather downturns. This capital conservatism supports long-term resilience versus peers with higher leverage.
Bears Say
2026 Revenue And Profit DeteriorationA material step-down in 2026 revenue and profits interrupts multi-year growth momentum and can slow instrument placements that drive future consumable and service sales. If persistent, the setback may constrain organic top-line drivers and extend recovery timelines for margins and cash flow.
Rising Total Debt LevelsDebt rising threefold over a few years reduces financial flexibility and raises interest and refinancing exposure if earnings remain weak. Higher leverage can limit capital allocation choices, increasing vulnerability to sustained revenue weakness or the need for external funding for strategic initiatives.
Volatile Free Cash Flow And Uneven Cash ConversionInconsistent free-cash-flow conversion and swings driven by working capital and investment create uncertainty in internal funding for capex, dividends and M&A. This variability raises the chance of interim external financing and complicates multi-quarter planning for growth investments.
Sysmex News
0YX FAQ
What was Sysmex Corporation’s price range in the past 12 months?
Sysmex Corporation lowest stock price was €6.51 and its highest was €14.90 in the past 12 months.
What is Sysmex Corporation’s market cap?
Sysmex Corporation’s market cap is €5.53B.
When is Sysmex Corporation’s upcoming earnings report date?
Sysmex Corporation’s upcoming earnings report date is Aug 07, 2026 which is in 2 days.
How were Sysmex Corporation’s earnings last quarter?
Sysmex Corporation released its earnings results on May 14, 2026. The company reported €0.016 earnings per share for the quarter, missing the consensus estimate of €0.033 by -€0.017.
Is Sysmex Corporation overvalued?
According to Wall Street analysts Sysmex Corporation’s price is currently Undervalued.
Does Sysmex Corporation pay dividends?
Sysmex Corporation does not currently pay dividends.
What is Sysmex Corporation’s EPS estimate?
Sysmex Corporation’s EPS estimate is 0.05.
How many shares outstanding does Sysmex Corporation have?
Sysmex Corporation has 629,480,100 shares outstanding.
What happened to Sysmex Corporation’s price movement after its last earnings report?
Sysmex Corporation reported an EPS of €0.016 in its last earnings report, missing expectations of €0.033. Following the earnings report the stock price went up 0.893%.
Which hedge fund is a major shareholder of Sysmex Corporation?
Currently, no hedge funds are holding shares in DE:0YX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.
0YX Stock 12 Month Forecast
Average Price Target
€9.37
▲(10.59% Upside)